Analysts expect that Eargo, Inc. (NASDAQ:EAR) will announce earnings of ($0.27) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Eargo's earnings. The lowest EPS estimate is ($0.35) and the highest is ($0.15). The company is expected to report its next quarterly earnings results after the market closes on Wednesday, May 12th.
According to Zacks, analysts expect that Eargo will report full-year earnings of ($1.00) per share for the current year, with EPS estimates ranging from ($1.28) to ($0.64). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.72) per share, with EPS estimates ranging from ($1.06) to ($0.40). Zacks' EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Eargo.
Eargo (NASDAQ:EAR) last posted its quarterly earnings data on Thursday, February 25th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.18). The company had revenue of $22.38 million for the quarter, compared to analysts' expectations of $22.20 million.
A number of brokerages recently issued reports on EAR. Zacks Investment Research raised shares of Eargo from a "hold" rating to a "buy" rating and set a $79.00 price target on the stock in a report on Tuesday, February 9th. Wells Fargo & Company increased their price target on shares of Eargo from $53.00 to $60.00 in a report on Wednesday, January 13th. Five equities research analysts have rated the stock with a buy rating, Eargo presently has a consensus rating of "Buy" and an average price target of $55.75.
In other Eargo news, Director Geoff Pardo sold 6,134 shares of the company's stock in a transaction on Tuesday, April 20th. The shares were sold at an average price of $48.04, for a total transaction of $294,677.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Healthcare Holding B.V. Gilde sold 7,666 shares of the stock in a transaction dated Wednesday, April 21st. The shares were sold at an average price of $47.97, for a total transaction of $367,738.02. The disclosure for this sale can be found here. Insiders have sold 630,258 shares of company stock valued at $32,639,339 over the last 90 days.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Calamos Advisors LLC raised its position in shares of Eargo by 3.4% in the first quarter. Calamos Advisors LLC now owns 31,105 shares of the company's stock valued at $1,554,000 after buying an additional 1,016 shares during the last quarter. RMR Wealth Builders acquired a new stake in Eargo during the fourth quarter worth about $45,000. Virtu Financial LLC acquired a new stake in Eargo during the fourth quarter worth about $204,000. Alyeska Investment Group L.P. acquired a new stake in Eargo during the fourth quarter worth about $2,956,000. Finally, JPMorgan Chase & Co. acquired a new stake in Eargo during the fourth quarter worth about $1,347,000.
Shares of NASDAQ EAR opened at $55.87 on Thursday. The business's fifty day moving average price is $50.85. Eargo has a 1 year low of $32.58 and a 1 year high of $76.75.
Eargo Company Profile
Eargo, Inc, a medical device company, develops and sells hearing aids to assist people with hearing loss in the United States. It sells its products through online stores. The company was formerly known as Aria Innovations, Inc and changed its name to Eargo, Inc in November 2014. Eargo, Inc was founded in 2010 and is headquartered in San Jose, California.
Read More: What are the most popular ETFs
Get a free copy of the Zacks research report on Eargo (EAR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What is the significance of a dead cat bounce?
7 Bellwether Stocks Signaling a Return to NormalBellwether stocks are considered to be leading indicators about the direction of the overall economy, a specific sector, or the broader market. They are predictive stocks in that investors can use the company’s earnings reports to gauge economic strength or weakness.
The traditional definition of bellwether stocks brings to mind established, blue-chip companies. They are the home of mature brands with consumer loyalty. These may be stocks that aren’t associated with exceptional growth; some may be dividend stocks.
But there’s something different about normal this time around. If it’s true (and I think it is) that the old rules no longer apply, investors need to change the way they think about bellwether stocks. Plus, let’s face it, many stocks that we might consider to be bellwether stocks have already had a bit of a vaccine rally. That means that the easy gains are gone.
With that in mind, we’ve put together this special presentation that highlights seven of what may be termed the new bellwether stocks. These are stocks that investors should be paying attention to as the economy continues to reopen.
One quality of many of these stocks is that they are either negative for 2021 or underperforming the broader market. And that means that they are likely to have a strong upside as the economy grows.
View the "7 Bellwether Stocks Signaling a Return to Normal".
